Beclometasone/formoterol

Beclometasone/formoterol
Combination of
Beclometasone dipropionateGlucocorticoid
Formoterol fumarateLong-acting β2 agonist
Names
Trade namesFostair; Fostair Nexthaler; Luforbec, others
Other namesBeclometasone/eformoterol[1]
Clinical data
Main usesAsthma, chronic obstructive pulmonary disease (COPD)[2]
Side effectsPneumonia, thrush, allergic reactions, low potassium, headache, glaucoma, blurry vision[2]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Routes of
use		Inhalation
Typical dose1 to 2 puffs BID[2]
External links
AHFS/Drugs.comInternational Drug Names
Legal
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only) [2][3][4]

Beclometasone/formoterol, sold under the brand name Fostair, is a combination medication used to treat asthma and chronic obstructive pulmonary disease (COPD).[2] In asthma it may be used both as long-term prevention and for sudden worsening.[5] It is a second line treatment.[2] It is used by breathing the medication in.[2]

Side effects are those of the two medications it contains.[2] These may include pneumonia, thrush, allergic reactions, low potassium, headache, glaucoma, and blurry vision.[2] Safety in pregnancy is unclear.[2] It contains beclometasone dipropionate, a corticosteroid; and formoterol fumarate dihydrate a long-acting β2 agonist (LABA).[2]

The combination was approved for medical use in the United Kingdom in 2007, and Australia in 2020.[2][1][6] It is on the World Health Organization's List of Essential Medicines as an alternative to budesonide/formoterol.[7] In the United Kingdom 120 doses costs the NHS about £30 as of 2023.[5]

Medical use

Dosage

It is often used as one to two puffs twice per day.[2] Up to 8 doses per day may be used.[5]

References

  1. 1 2 "Australian Product Information - Fostair 100/6 (Beclometasone dipropionate and formoterol (eformoterol) fumarate dihydrate) pressurised inhalation solution". Therapeutic Goods Administration (TGA). April 2020. Archived from the original on 20 January 2021. Retrieved 22 September 2020.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 "Fostair 100/6 micrograms per actuation pressurised inhalation solution - Summary of Product Characteristics (SmPC)". (emc). 3 March 2020. Archived from the original on 19 July 2020. Retrieved 18 July 2020.
  3. ↑ "Fostair 200/6 micrograms per actuation pressurised inhalation solution - Summary of Product Characteristics (SmPC)". (emc). 13 February 2019. Archived from the original on 19 July 2020. Retrieved 18 July 2020.
  4. ↑ "Fostair NEXThaler 200 micrograms/6 micrograms per actuation inhalation powder - Summary of Product Characteristics (SmPC)". (emc). 16 April 2019. Archived from the original on 19 July 2020. Retrieved 18 July 2020.
  5. 1 2 3 BNF 84 (British National Formulary) September 2022 (84 ed.). Pharmaceutical Press. 2022. p. X. ISBN 978-0857114327.
  6. ↑ "AusPAR: Beclometasone dipropionate/formoterol (eformoterol) fumarate dihydrate". Therapeutic Goods Administration (TGA). 3 August 2020. Archived from the original on 1 October 2020. Retrieved 22 September 2020.
  7. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
Identifiers:
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.